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Introduction {#s1}
============

One in six couples worldwide is affected by infertility, which is defined as the inability to get pregnant after 1 y or more of unprotected intercourse ([@c8]), and a recent U.S. study found that pregnancy loss (miscarriage) affected approximately 28% of couples planning a pregnancy ([@c2]). These figures will likely rise as the postponement of childbearing increases in developed regions of the world. Infertility has an associated health-care cost in the billions of dollars per year, not including the physical and psychological burden placed on the couple ([@c9]). Both the high rates of fertility along with the associated high costs highlight the need to improve our understanding of risk factors that impair the ability to have a child.

One potential risk factor is environmental exposure. Several classes of endocrine-disrupting chemicals (EDCs) with widespread general population exposure, including pesticides and phthalates, have been linked to infertility and adverse pregnancy outcomes ([@c11]). While there are hundreds or more EDCs, only a fraction have been evaluated for effects on infertility and pregnancy ([@c15]). Organophosphate flame retardants (PFRs) are a class of EDCs with ubiquitous exposure that have been detected in 90--100% of adult urine samples ([@c4], [@c5]; [@c6]; [@c16]; [@c17]; [@c21]). Over the past decade, PFRs have been used widely in the polyurethane foam of upholstered furniture as replacements for pentabromodiphenyl ether, a flame retardant mixture that was phased out of use in 2005 ([@c28]). These chemicals are not chemically bonded to foam and have been shown to migrate into the air and dust of indoor environments ([@c31]). The PFR triphenyl phosphate (TPHP) is used as part of flame retardant mixtures in polyurethane foam as well as in a variety of other applications, including as a plasticizer ([@c35]).

Animal studies indicate that exposure to PFRs can disrupt endocrine function through altered thyroid action, steroidogenesis, or estrogen metabolism, and can also impair embryo development ([@c14]; [@c20]; [@c33]). Reductions in sperm motility and increased serum total $T_{3}$ levels were associated with increasing PFR exposures in a small study of men ([@c22]); however, no studies have investigated the effect of PFRs on pregnancy outcomes. Therefore, we explored the association between urinary concentrations of PFRs and pregnancy outcomes among women in a prospective cohort study, the Environment And Reproductive Health (EARTH) study, using assisted reproductive technologies (ART) as a model to study early developmental endpoints and pregnancy outcomes.

Methods {#s2}
=======

Participants {#s2.1}
------------

Study participants were women recruited into the EARTH study, which was established in June 2004 to evaluate environmental and dietary determinants of fertility from patients undergoing ART at the Massachusetts General Hospital (MGH) Fertility Center. Women between the ages of 18 and 46 were eligible to participate, and approximately 60% of those contacted by the research nurses enrolled in the study. The EARTH study was approved by the Human Studies Institutional Review Boards of the MGH and Harvard T.H. Chan School of Public Health. Participants signed an informed consent after the study procedures were explained by trained study staff and any questions were answered. Demographic information including race/ethnicity, smoking history, and education, as well as whether they had a previous pregnancy, were recorded at study entry by the participant using a questionnaire. To be included in the present analysis, women must have contributed their own oocytes and at least one urine sample for the measurement of flame retardant metabolites during an *in vitro* fertilization (IVF) cycle. From the 212 women (298 IVF cycles) who met these criteria, we excluded 1 woman (1 IVF cycle) with incomplete outcome data. Our final data set included 211 women with 297 IVF cycles who had complete information on the exposure and outcome variables.

Clinical Data and *in Vitro* Fertilization Outcomes {#s2.2}
---------------------------------------------------

At study entry, the participant's date of birth was collected, and her weight and height were measured by trained study staff. Body mass index (BMI) was calculated as weight (in kilograms) per height (in meters) squared. Clinical information was collected or abstracted from the patient's electronic medical record by trained study staff at enrollment into the study and after each IVF cycle. Follicle stimulating hormone (FSH) was measured in a blood sample drawn on the third day of the menstrual cycle and analyzed for with an automated electrochemiluminescence immunoassay at the MGH Core Laboratory as previously described ([@c23]). Cause of infertility was diagnosed by a physician at the MGH Fertility Center according to the Society for Assisted Reproductive Technology (SART) using standard infertility definitions ([@c25]; [@c23]). IVF treatment protocols were assigned by a physician at the MGH Fertility Center based on clinical indications and factors such as age and infertility diagnosis. Treatment protocols include: *a*) luteal phase gonadotropin-releasing hormone (GnRH) agonist (low-, regular-, or high-dose leuprolide acetate; Lupron); *b*) follicular phase GnRH agonist/flare stimulation; or *c*) GnRH antagonist. Lupron dose was reduced at, or shortly after, the start of ovarian stimulation with FSH/human menopausal gonadotropin (hMG) in the luteal phase GnRH agonist protocol. Serum peak estradiol ($\text{pmol}/\text{L}$) was measured on the day of ovulation trigger with human chorionic gonadotropin (hCG) \[estradiol ($\text{E}_{2}$) trigger levels\] using an automated electrochemiluminescence immunoassay at the MGH Core Laboratory. Oocytes were counted and classified by embryologists after egg retrieval as germinal vesicle, metaphase I, metaphase II, or degenerated. Fertilization was obtained by conventional IVF or intracytoplasmatic sperm injection (ICSI). Fertilization was confirmed 17--20 h after insemination by the presence of a fertilized oocyte with two pronuclei. Embryos were monitored for cell number and morphological quality \[1 (best) to 5 (worst)\] on days 2 and 3, and considered of best quality if they had a score of 1 or 2. Transfer occurred rarely on day 2, with the majority on day 3 or 5 and comprised of cleavage stage and blastocyst stage embryos, respectively. Most women had 1--3 embryos transferred ($\text{range} = 0–5$), with the number dependent on the woman's age, cycle number. and the day of transfer. Implantation was defined as a serum $\beta - \text{hCG}\,\text{level} > 6\,\text{mIU}/{mL}$ approximately 17 d ($\text{range} = 15–20\,\text{d}$) after egg retrieval, clinical pregnancy as the presence of an intrauterine pregnancy confirmed by ultrasound at approximately 6-wk gestation, and live birth as the birth of a neonate on or after 24-wk gestation.

Organophosphate Flame Retardant Assessment in Urine Samples {#s2.3}
-----------------------------------------------------------

Urine samples were collected from participants enrolled in the EARTH study between May 2005 and January 2015. Each sample was collected into a sterile polypropylene cup, and up to two urine samples were collected during each IVF cycle. Urine samples were collected at a geometric mean (GM) \[95% confidence interval (CI)\] of 7.6 (7.3, 8.0) d apart with 178 (141, 215) d between the first and second IVF cycle. Following collection of each sample, specific gravity (SG) was measured using a Protometer (hand held) Model 100B refractometer (National Instrument Company, Inc.); the urine sample was divided into aliquots and frozen at $- 80{^\circ}C$. Samples were shipped on dry ice overnight to H.M. Stapleton's lab at Duke University (Durham, NC) for the quantification of the PFR metabolites ([Figure 1](#f1){ref-type="fig"}).

![Organophosphate flame retardant parent compound and primary urinary metabolite.](EHP1021_f1){#f1}

Extraction and analysis methods for bis(1-chloro-2-propyl) phosphate (BCIPP), bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), diphenyl phosphate (DPHP), isopropylphenyl phenyl phosphate (ip-PPP), and tert-butylphenyl phenyl phosphate (tb-PPP) followed methods previously developed by H.M. Stapleton's laboratory ([@c4]). Briefly, urine samples were thawed, and a 2.5- to $5 - {mL}$ aliquot was transferred to a clean glass test tube, where it was spiked with mass-labeled internal standards ($d_{10} - \text{BDCIPP} = 80\,\text{ng}$, $d_{10} - \text{DPHP} = 60\,\text{ng}$). After acidifying to pH $< 6.5$ with formic acid, samples were diluted 1:1 with water and concentrated and cleaned using solid-phase extraction techniques (SPE). The SPE eluent was blown to dryness under a gentle nitrogen stream, reconstituted in $500\;\mu L$ of 1:1 $H_{2}O:\text{MeOH}$ and spiked with the recovery standard (${}^{13}C_{2} - \text{DPHP} = 81.5\,\text{ng}$). Extracts were analyzed by negative electrospray ionization liquid chromatography tandem mass spectrometry (LC-MS/MS) as previously described ([@c4]). Chromatography was achieved under gradient conditions using a Luna C18(2) column ($50 \times 2.0\;{mm}$, $2.5\;\mu m$ particle size, Phenomenex) preceded by a SecurityGuard Polar-RP ($4 \times 2.0\;{mm}$) guard cartridge (Phenomenex). The mobile phases were methanol and water (modified with $0.8\,\text{mM}$ ammonium acetate), flow rate was $300\;\mu L/\text{min}$, the injection volume was $5\;\mu L$, and the column oven was 45°C. Data were acquired under multiple reaction monitoring conditions using optimized parameters. Analyte responses were normalized to internal standard responses. BCIPP and BDCIPP were normalized using $d_{10} - \text{BDCIPP}$, while DPHP, ip-PPP, and tb-PPP were normalized using $d_{10} - \text{DPHP}$. Urinary SG ranged from 1.002 to 1.028 with a mean of 1.016.

Samples were analyzed by LC-MS/MS in 10 separate batches, and unique method detection limits (MDLs) were calculated for each analysis batch. In the urine samples, the mean recovery of the mass-labeled standards was 119% ($\text{standard}\,\text{error} = 0.75\%$) for $d_{10} - \text{DPHP}$ and 152% (2.2%) for $d_{10} - \text{BDCIPP}$. One laboratory blank ($5\;{mL}$ MilliPore water only) sample was extracted with every batch ($n = 95$). An in-house standard reference material (SRM) was prepared from pooled urine that was collected during previous studies. SRM samples were periodically analyzed during the extraction batches ($n = 18$) and were generally within 10% for DPHP, 15% for BDCIPP, and 20% for ip-PPP. Two of the individual subsamples were analyzed in duplicate to assess method precision and were generally within 15% for DPHP, 25% for ip-PPP, and 35% for BDCIPP. Very low levels of DPHP ($\text{mean} = 0.58\,\text{ng}$) and ip-PPP ($\text{mean} = 0.21\,\text{ng}$) were commonly detected in the laboratory blanks, and analyte values were blank corrected using the mean laboratory blank values. MDLs were calculated as three times the standard deviation of laboratory blanks normalized to the volume of water extracted ($5\;{mL}$). MDLs ranged ($n = 10$) from $68–180\,\text{pg}/{mL}$ for BCIPP, $31–300\,\text{pg}/{mL}$ for BDCIPP, $25–130\,\text{pg}/{mL}$ for DPHP, and $23–120\,\text{pg}/{mL}$ for ip-PPP, and $10–150\,\text{pg}/{mL}$ for tb-PPP, respectively.

Data Analysis {#s2.4}
-------------

Demographic and clinical characteristics were reported using $\text{mean} \pm \text{interquartile}\,\text{range}$ or percentages. Unquantified concentrations $< \text{MDL}$ were substituted with a value equal to the $\text{MDL}/\left. \sqrt{}2 \right.$ ([@c19]). To account for urinary dilution, we adjusted to SG as described by Pearson et al. ([@c24]): $C_{\text{SG}} = C*\left\lbrack {\left( {\text{SG}_{m} - 1} \right)/\left( {\text{SG}_{i} - 1} \right)} \right\rbrack$ where $C_{\text{SG}} = \text{SG} - \text{adjusted}\,\text{urinary}\,\text{metabolite}\,\text{concentration}$, $C = \text{urinary}\,\text{metabolite}\,\text{concentration}$, $\text{SG}_{m} = \text{mean}\,\text{SG}$ for the population, and $\text{SG}_{i} = \text{SG}$ for an individual sample. Cycle-specific urinary metabolite concentrations were calculated using the GM of the two urinary metabolite concentrations from each IVF cycle. Cycle-specific concentrations were divided into quartiles for use in regression models. All analyses used the SG-adjusted urinary metabolite concentrations.

To evaluate the associations between the urinary metabolites and IVF outcomes, we fit multivariable generalized linear mixed models with random intercepts to account for multiple IVF cycles in the same woman. These models allow for the use of multiple outcome observations per individual while accounting for within-person correlations in outcomes. These models are also appropriate and can provide unbiased estimates in the presence of an unbalanced design (e.g., different number of cycles contributed per woman) when imbalance in the number of IVF cycles is not completely random (e.g., women with more cycles are having more difficulty getting pregnant), and the lack of balance can be accurately predicted by all measured covariates in the adjusted model. A normal distribution and identity link function was specified for peak estradiol and endometrial lining thickness. A Poisson distribution and log link function were specified for the number of mature and total oocytes as well as best quality embryo. A binomial distribution and logit link function were spcified for fertilization and the proportion of mature to total oocytes. Finally, a binary distribution with a logit link function were specified for the clinical outcomes (implantation, clinical pregnancy, and live birth). Tests for trend were conducted across quartiles using the median log-transformed urinary metabolite concentration in each quartile as a linear variable in the regression models. To allow for better interpretation of the results, all results are presented as population marginal means adjusted for covariates. Percent decrease was calculated as the difference in marginal means from Q1 to Q4 divided by the marginal mean from Q1.

We evaluated confounding using prior knowledge and descriptive statistics from our cohort. The following covariates were considered for inclusion in the final model: maternal age (continuous), race/ethnic group (black/Asian/other, white/Caucasian), BMI (continuous), smoking history (ever, never), education (high school, college graduate, graduate degree), year of IVF treatment cycle (continuous), and primary infertility diagnosis (female factor, male factor, and unexplained). Variables were included in the final model if they were associated with any of the individual PFR metabolites (BDCIPP, DPHP, ip-PPP) in our population, were suspected to be associated with exposure based on previous research, or were strong predictors of the outcome. In our primary analysis of the early developmental outcomes, we excluded seven women (16 IVF cycles) with unsuccessful oocyte retrieval, and applied this restriction in a sensitivity analysis for the clinical outcomes. We tested whether the associations of urinary metabolite concentrations with fertilization were modified by ICSI by entering a product of the metabolite quartiles and a binary variable representing the presence or absence of ICSI into the models. Given our limited sample size for detecting interactions, a suggestion of interaction was considered if the *p*-value for this interaction term was $< 0.10$. Finally, we tested for a potential cohort effect by controlling for maternal year of birth, rather than maternal age, in our adjusted model.

We evaluated the relationship between urinary PFR metabolites using Spearman's correlation and estimated the variability of urinary metabolite concentrations within a cycle and for all cycles by calculating the intraclass correlation coefficient (ICC). We conducted all statistical analyses using SAS (version 9.2; SAS Institute Inc.), and all tests other than interaction with ICSI considered two-sided significance levels less than 0.05 as statistically significant.

Results {#s3}
=======

Study Population {#s3.1}
----------------

Our analysis included 211 women who were on average 35.0 y of age; 87% were Caucasian, 75% had never smoked, and 34% had a prior pregnancy ([Table 1](#t1){ref-type="table"}). The primary SART diagnosis was approximately equally distributed between female factor (36%), male factor (29%), and unexplained (35%).

###### 

Demographic and reproductive characteristics of 211 women \[297 *in vitro* fertilization (IVF) cycles\] in the Environment and Reproductive Health (EARTH) study.

Table 1 lists characteristics and total cohort median (IQR) or N (percent) in the first and the second column, respectively.

  Characteristics                                                                   Total cohort median (IQR) or $n$ (%)
  --------------------------------------------------------------------------------- --------------------------------------
  Demographic characteristics                                                        
   Age, years                                                                       35.0 (32.0, 37.0)
   Race/ethnic group, $n$ (%)                                                        
    Black/Asian/other                                                               28 (13)
    White/Caucasian                                                                 183 (87)
   Body mass index, ${{kg}/m}^{2}$                                                  22.8 (20.8, 25.8)
   Ever smoker, $n$ (%)                                                             52 (25)
   Education, $n$ (%)[^*a*^](#t1n2){ref-type="table-fn"}                             
    High school/some college                                                        12 (6)
    College graduate                                                                71 (37)
    Graduate degree                                                                 109 (57)
  Reproductive/cycle characteristics                                                 
   History of ever been pregnant                                                    71 (34)
   Day 3 FSH levels, IU/L                                                           6.7 (5.9, 8.1)
   Initial infertility diagnosis, $n$ (%)                                            
    Female factor                                                                   75 (36)
    Male factor                                                                     62 (29)
    Unexplained                                                                     74 (35)
   Previous intrauterine insemination, $n$ (%)[^*a*^](#t1n2){ref-type="table-fn"}   85 (41)
   Previous *in vitro* fertilization, $n$ (%)[^*a*^](#t1n2){ref-type="table-fn"}    43 (21)
   Treatment protocol, $n$ (%)                                                       
    Antagonist                                                                      37 (13)
    Flare[^*b*^](#t1n3){ref-type="table-fn"}                                        54 (18)
    Luteal phase agonist[^*c*^](#t1n4){ref-type="table-fn"}                         206 (69)
   E~2~ trigger levels, $\text{pmol}/\text{L}$                                      1,965 (1,517, 2,570)
   ICSI cycles, $n$ (%)                                                             167 (56)
   Cycle canceled prior to transfer, $n$ (%)                                        16 (5)
   Embryo transfer day, $n$ (%)                                                      
    Number of embryos transferred                                                   16 (5)
    Day 2                                                                           16 (5)
    Day 3                                                                           163 (55)
    Day 5                                                                           102 (35)
   Number of embryos transferred, $n$ (%)                                            
    0 embryos                                                                       16 (5)
    1 embryo                                                                        56 (19)
    2 embryos                                                                       162 (55)
    $\geq 3$ embryos                                                                63 (21)

Note: $\text{E}_{2}$, estradiol; FSH, follicle stimulating hormone; ICSI, intracytoplasmatic sperm injection; IQR, interquartile range.

Has missing data (19 missing education; 3 missing previous IUI and IVF).

Follicular phase GnRH agonist/flare protocol.

Luteal phase GnRH agonist protocol.

Urinary Organophosphate Flame Retardant Metabolites {#s3.2}
---------------------------------------------------

Detection frequencies were high for BDCIPP (87%), DPHP (94%), and ip-PPP (80%), but low for tb-PPP (14%) and BCIPP (0%) ([Table 2](#t2){ref-type="table"}). Concentrations of DPHP were 19% higher than BDCIPP on average and 252% higher than ip-PPP. Due to the $\text{pmol}/\text{L}$ low detection frequencies for tb-PPP and BCIPP, central tendency values were not calculated and statistical analysis was not performed for these urinary metabolites. BDCIPP was weakly but significantly correlated with DPHP ($r_{s} = 0.21$, $p = 0.002$) and ip-PPP ($r_{s} = 0.25$, $p = 0.0003$); DPHP and ip-PPP were also weakly correlated ($r_{s} = 0.19$, $p = 0.006$). ICCs indicated moderate within-person variability across cycles ($\text{BDCIPP} = 0.36$; $\text{DPHP} = 0.34$; $\text{ip} - \text{PPP} = 0.37$), with somewhat higher reproducibility within a cycle ($\text{BDCIPP} = 0.48$; $\text{DPHP} = 0.53$; $\text{ip} - \text{PPP} = 0.44$).

###### 

Distribution of urinary organophosphate flame retardant metabolites ($\text{ug}/\text{L}$) measured among 211 women with 297 cycles and 563 urine samples in the Environment And Reproductive Health (EARTH) study.

Table 2 lists metabolites in the first column and the values (percent) of N greater than MDL in the second column; the corresponding values for GM (95 percent confidence interval), minimum, 10th percentile, 25th percentile, 50th percentile, 75th percentile, 90th percentile, 95th percentile, and maximum are listed in the other columns.

  Sample                                                         $\mathit{N} > {MDL}$   GM (95% CI)         Min              10th pctl           25th pctl        50th pctl        75th pctl        90th pctl        95th pctl           Max
  -------------------------------------------------------------- ---------------------- ------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Specific gravity adjusted[^*a*^](#t2n1){ref-type="table-fn"}                                                                                                                                                                             
   BCIPP                                                         0 (0.0)                NA                  $< \text{MDL}$   $< \text{MDL}$    $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$
   BDCIPP                                                        487 (87)               0.68 (0.62, 0.75)   $< \text{MDL}$   $< \text{MDL}$         0.32             0.69             1.40             3.30             5.08             63.4
   DPHP                                                          527 (94)               0.81 (0.75, 0.89)   $< \text{MDL}$   $< \text{MDL}$         0.43             0.75             1.28             3.10             5.25             616
   ip-PPP                                                        450 (80)               0.23 (0.21, 0.25)   $< \text{MDL}$   $< \text{MDL}$         0.12             0.24             0.44             0.77             1.18             71.4
   tb-PPP                                                        81 (14)                NA                  $< \text{MDL}$   $< \text{MDL}$    $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$        0.27             0.38             351
  Wet weight (not specific gravity adjusted)                                                                                                                                                                                               
   BCIPP                                                         0 (0.0)                NA                  $< \text{MDL}$   $< \text{MDL}$    $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$
   BDCIPP                                                        487 (87)               0.66 (0.59, 0.73)   $< \text{MDL}$   $< \text{MDL}$         0.29             0.69             1.68             3.65             5.76             63.4
   DPHP                                                          527 (94)               0.78 (0.71, 0.87)   $< \text{MDL}$   $< \text{MDL}$         0.40             0.79             1.49             3.50             5.92             657
   ip-PPP                                                        450 (80)               0.22 (0.20, 0.25)   $< \text{MDL}$   $< \text{MDL}$         0.09             0.24             0.49             0.94             1.37             79.5
   tb-PPP                                                        81 (14)                NA                  $< \text{MDL}$   $< \text{MDL}$    $< \text{MDL}$   $< \text{MDL}$   $< \text{MDL}$        0.11             0.25             374

Note: All values below MDL were assigned a value equal to the MDL divided by $\left. \sqrt{}2 \right.$. BCIPP, bis(1-chloro-2-propyl) phosphate; BDCIPP, bis(1,3-dichloro-2-propyl)phosphate; CI, confidence interval; DPHP, diphenyl phosphate; GM, geometric mean; ip-PPP, isopropylphenyl phenyl phosphate; Max, maximum; $< \text{MDL}$, methoddetectionlimit; Min, minimum; NA, not applicable; pctl, percentile; tb-PPP, tert-butylphenyl phenyl phosphate.

Adjusted to specific gravity, range (1.001--1.10).

Demographic variables associated with urinary PFR concentrations included age (BDCIPP and DPHP), BMI (BDCIPP), and year (ip-PPP). For every unit increase in age, there was a 4% ($p = 0.05$) and 3% ($p = 0.04$) decline in mean urinary BDCIPP and DPHP concentrations. For every unit increase in BMI, there was a 4% ($p = 0.03$) increase in urinary BDCIPP, and every year, there was a 7% ($p = 0.002$) decline in urinary ip-PPP concentrations. There were no other significant associations with the demographic variables, and no associations of urinary PFR quartiles with reproductive/cycle characteristics were observed.

*In Vitro* Fertilization Outcomes {#s3.3}
---------------------------------

We observed significant declines in adjusted means from the lowest to highest quartile of $\Sigma\text{PFR}$ for the proportion of cycles resulting in successful fertilization (10% decrease, $p - \text{trend} = 0.04$), implantation (31%, $p - \text{trend} = 0.02$), clinical pregnancy (41%, $p - \text{trend} = 0.004$) and live birth (38%, $p - \text{trend} = 0.05$), adjusted for age, BMI, race/ethnicity, year of cycle, and infertility diagnosis ([Figure 2](#f2){ref-type="fig"}, [Tables 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}). There were also significant declines in adjusted means from the highest to lowest quartile of DPHP for the proportion of cycles resulting in successful implantation (28% decrease, $p - \text{trend} = 0.02$) and clinical pregnancy (36%, $p - \text{trend} = 0.01$) as well as for ip-PPP for the proportion of cycles resulting in successful fertilization (16%, $p - \text{trend} = 0.0006$), implantation (27%, $p - \text{trend} = 0.05$), and live birth (34%, $p - \text{trend} = 0.05$). Unadjusted results were similar (Table S1). Results for the clinical outcomes were similar when restricted to IVF cycles with successful oocyte retrieval, restricted to the first cycle in the EARTH study, restricted to nulliparous women, or controlling for maternal year of birth (Table S2).

![Adjusted mean \[95% confidence interval (CI)\] proportion of cycles resulting in implantation, live birth, and clinical pregnancy by quartile of urinary organophosphate flame retardant (PFR) metabolite concentrations among 211 women undergoing 297 *in vitro* fertilization (IVF) cycles. Gray shading indicates change in means from the first and fourth quartile. Adjusted models control for maternal age (continuous), body mass index (BMI) (continuous), race/ethnicity (black/Asian/other, white/Caucasian), year of IVF treatment cycle (continuous), and primary Society for Assisted Reproductive Technology (SART) infertility diagnosis at study entry (female, male, unknown), with continuous variables at their mean level and categorical variables weighted by their frequency in the study population. \*Significantly different from the lowest quartile (Q1) at the $\alpha = 0.05$ level.](EHP1021_f2){#f2}

###### 

Adjusted mean \[95% confidence interval (CI)\] proportion of cycles resulting in implantation, live birth, and clinical pregnancy by quartile of urinary organophosphate flame retardant metabolite concentrations among 211 women undergoing 297 *in vitro* fertilization (IVF) cycles.

Table 3 lists quartiles for fertilization in the first column; the corresponding values for gamma PFR, BDCIPP, DPHP, and ip-PPP are listed in the other columns.

  Condition      $\Sigma\text{PFR}$                                    BDCIPP              DPHP                                                  ip-PPP
  -------------- ----------------------------------------------------- ------------------- ----------------------------------------------------- -----------------------------------------------------
  Implantation                                                                                                                                    
   Q1            0.71 (0.59, 0.81)                                     0.72 (0.59, 0.81)   0.69 (0.56, 0.79)                                     0.74 (0.62, 0.83)
   Q2            0.62 (0.49, 0.73)                                     0.58 (0.46, 0.70)   0.64 (0.52, 0.75)                                     0.50 (0.37, 0.62)
   Q3            0.57 (0.45, 0.69)                                     0.53 (0.41, 0.65)   0.56 (0.44, 0.68)                                     0.61 (0.48, 0.72)
   Q4            0.49 (0.37, 0.62)[^\*^](#t2n2){ref-type="table-fn"}   0.56 (0.43, 0.67)   0.50 (0.38, 0.62)[^\*^](#t2n2){ref-type="table-fn"}   0.54 (0.41, 0.66)[^\*^](#t2n2){ref-type="table-fn"}
  * p*-trend     0.02                                                  0.06                0.02                                                  0.05
  Pregnancy                                                                                                                                       
   Q1            0.63 (0.50, 0.74)                                     0.61 (0.49, 0.73)   0.61 (0.49, 0.72)                                     0.63 (0.51, 0.74)
   Q2            0.54 (0.42, 0.66)                                     0.50 (0.38, 0.62)   0.55 (0.42, 0.66)                                     0.40 (0.29, 0.53)
   Q3            0.50 (0.38, 0.62)                                     0.47 (0.35, 0.59)   0.48 (0.36, 0.60)                                     0.51 (0.39, 0.63)
   Q4            0.37 (0.26, 0.50)[^\*^](#t2n2){ref-type="table-fn"}   0.45 (0.33, 0.57)   0.39 (0.28, 0.52)[^\*^](#t2n2){ref-type="table-fn"}   0.48 (0.36, 0.61)
  * p*-trend     0.004                                                 0.06                0.01                                                  0.19
  Live birth                                                                                                                                      
   Q1            0.48 (0.35, 0.61)                                     0.49 (0.36, 0.61)   0.47 (0.34, 0.59)                                     0.53 (0.40, 0.65)
   Q2            0.42 (0.30, 0.55)                                     0.36 (0.24, 0.48)   0.42 (0.30, 0.55)                                     0.35 (0.24, 0.47)
   Q3            0.38 (0.27, 0.51)                                     0.36 (0.25, 0.49)   0.37 (0.26, 0.50)                                     0.35 (0.24, 0.48)
   Q4            0.30 (0.20, 0.43)[^\*^](#t2n2){ref-type="table-fn"}   0.36 (0.25, 0.49)   0.31 (0.21, 0.44)                                     0.35 (0.24, 0.48)
  * p*-trend     0.05                                                  0.20                0.07                                                  0.05

Note: Adjusted models control for maternal age (continuous), body mass index (continuous), race/ethnicity (black/Asian/other, white/Caucasian), year of IVF treatment cycle (continuous), and primary Society for Assisted Reproductive Technology (SART) infertility diagnosis at study entry (female, male, unknown). Adjusted means are presented for the mean maternal age (35.2), body mass index (23.9), race/ethnicity (white), year of IVF treatment cycle (2010), and primary SART infertility diagnosis at study entry ($\text{female} = 1$ $\text{male} = 0$, $\text{unexplained} = 0$). BDCIPP, bis(1,3-dichloro-2-propyl) phosphate; DPHP, diphenyl phosphate; ip-PPP, isopropylphenyl phenyl phosphate; PFR, organophosphate flame retardant.

Significantly different from Q1 at the $p = 0.05$ level.

###### 

Adjusted means \[95% confidence interval (CI)\] for early developmental outcomes by quartile of urinary organophosphate flame retardant metabolite concentrations among 205 women undergoing 281 *in vitro* fertilization (IVF) cycles that had oocyte retrieval.

Table 4 lists quartiles for the early developmental outcomes in the first column; the corresponding values for gamma PFR, BDCIPP, DPHP, and ip-PPP are listed in the other columns.

  Characteristic                          $\Sigma\text{PFR}$                                    BDCIPP                                                DPHP                                                  ip-PPP
  --------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  $\text{E}_{2}$ trigger levels, pmol/L                                                                                                                                                                      
   Q1                                     1,939 (1,766, 2,112)                                  1,995 (1,821, 2,169)                                  1,969 (1,794, 2,145)                                  2,028 (1,855, 2,200)
   Q2                                     2,163 (1,992, 2,333)                                  2,061 (1,889, 2,233)                                  2,120 (1,946, 2,293)                                  2,097 (1,927, 2,267)
   Q3                                     2,007 (1,838, 2,176)                                  2,015 (1,842, 2,188)                                  2,143 (1,970, 2,317)                                  2,153 (1,985, 2,322)
   Q4                                     2,123 (1,947, 2,299)                                  2,155 (1980, 2,331)                                   1,994 (1,817, 2,171)                                  1,950 (1,773, 2,128)
  * p*-trend                              0.26                                                  0.25                                                  0.99                                                  0.71
  Total oocytes, count                                                                                                                                                                                       
   Q1                                     10.6 (9.6, 11.8)                                      9.9 (8.9, 11.0)                                       11.0 (9.9, 12.2)                                      10.7 (9.6, 11.9)
   Q2                                     11.1 (10.0, 12.3)                                     11.4 (10.3, 12.7)                                     11.1 (10.0, 12.3)                                     10.9 (9.8, 12.1)
   Q3                                     10.8 (9.8, 12.0)                                      11.1 (10.0, 12.3)                                     11.3 (10.2, 12.6)                                     11.9 (10.7, 13.1)
   Q4                                     11.5 (10.3, 12.8)                                     11.7 (10.6, 13.0)[^\*^](#t3n2){ref-type="table-fn"}   10.7 (9.6, 11.9)                                      10.7 (9.5, 11.9)
  * p*-trend                              0.34                                                  0.04                                                  0.69                                                  0.68
  Total MII oocytes, count                                                                                                                                                                                   
   Q1                                     9.2 (8.2, 10.3)                                       8.5 (7.6, 9.5)                                        9.3 (8.3, 10.4)                                       8.9 (7.9, 9.9)
   Q2                                     9.4 (8.4, 10.5)                                       9.4 (8.4, 10.5)                                       9.5 (8.5, 10.6)                                       9.3 (8.4, 10.4)
   Q3                                     8.8 (7.9, 9.8)                                        9.3 (8.3, 10.3)                                       9.4 (8.4, 10.5)                                       10.1 (9.1, 11.2)
   Q4                                     9.6 (8.6, 10.7)                                       9.8 (8.8, 10.9)                                       8.8 (7.8, 9.9)                                        8.6 (7.7, 9.7)
  * p*-trend                              0.71                                                  0.10                                                  0.44                                                  0.87
  Fertilization, proportion                                                                                                                                                                                  
   Q1                                     0.77 (0.72, 0.81)                                     0.75 (0.70, 0.79)                                     0.75 (0.70, 0.79)                                     0.77 (0.72, 0.81)
   Q2                                     0.72 (0.67, 0.76)                                     0.73 (0.68, 0.77)                                     0.68 (0.63, 0.73)                                     0.75 (0.71, 0.79)
   Q3                                     0.71 (0.66, 0.76)                                     0.71 (0.66, 0.76)                                     0.78 (0.73, 0.82)                                     0.71 (0.66, 0.75)
   Q4                                     0.70 (0.65, 0.74)[^\*^](#t3n2){ref-type="table-fn"}   0.71 (0.66, 0.76)                                     0.68 (0.63, 0.73)[^\*^](#t3n2){ref-type="table-fn"}   0.65 (0.60, 0.70)[^\*^](#t3n2){ref-type="table-fn"}
  * p*-trend                              0.04                                                  0.27                                                  0.17                                                  0.0006
  Best quality embryos, count                                                                                                                                                                                
   Q1                                     1.6 (1.3, 2.1)                                        1.5 (1.1, 1.9)                                        1.6 (1.2, 2.1)                                        1.5 (1.1, 1.9)
   Q2                                     1.5 (1.2, 2.0)                                        1.3 (1.0, 1.7)                                        1.4 (1.1, 1.9)                                        1.8 (1.4, 2.3)
   Q3                                     1.4 (1.0, 1.8)                                        1.6 (1.3, 2.1)                                        1.6 (1.3, 2.1)                                        1.5 (1.2, 2.0)
   Q4                                     1.5 (1.1, 1.9)                                        1.5 (1.2, 2.0)                                        1.4 (1.0, 1.8)                                        1.2 (0.9, 1.6)
  * p*-trend                              0.48                                                  0.66                                                  0.51                                                  0.24
  Endometrial wall thickness, mm                                                                                                                                                                             
   Q1                                     10.3 (9.79, 10.8)                                     10.2 (9.7, 10.7)                                      10.2 (9.7, 10.8)                                      10.1 (9.6, 10.6)
   Q2                                     10.3 (9.79, 10.8)                                     10.2 (9.7, 10.7)                                      10.2 (9.7, 10.7)                                      10.1 (9.6, 10.6)
   Q3                                     9.80 (9.31, 10.3)                                     9.9 (9.4, 10.4)                                       10.1 (9.6, 10.6)                                      9.8 (9.3, 10.3)
   Q4                                     9.94 (9.42, 10.5)                                     10.0 (9.5, 10.5)                                      9.8 (9.3, 10.3)                                       10.3 (9.8, 10.8)
  * p*-trend                              0.19                                                  0.44                                                  0.15                                                  0.82

Note: Adjusted models control for maternal age (continuous), body mass index (continuous), race/ethnicity (black/Asian/other, white/Caucasian), year of IVF treatment cycle (continuous), and primary Society for Assisted Reproductive Technology (SART) infertility diagnosis at study entry (female, male, unknown). Adjusted means are presented for the mean maternal age (35.2), body mass index (24.0), race/ethnicity (white), year of IVF treatment cycle (2010), and primary SART infertility diagnosis at study entry ($\text{female} = 1$, $\text{male} = 0$ $\text{unexplained} = 0$). BDCIPP, bis(1,3-dichloro-2-propyl) phosphate; DPHP, diphenyl phosphate; ip-PPP, isopropylphenyl phenyl phosphate; PFR, organophosphate flame retardant.

Significantly different from Q1 at the $p = 0.05$ level.

The proportion of fertilized oocytes was significantly lower in the highest quartile (Q4) of urinary ip-PPP compared to the lowest (Q1) with an adjusted difference in proportions (95% CI) of 0.10 (0.02, 0.19) using conventional fertilization that was smaller and nonsignificant when restricted to fertilization using ICSI \[adjusted difference in $\text{proportions} = 0.04$ ($95\%\,\text{CI} = - 0.02$, 0.10)\]. However, the interaction term by ICSI on the association of urinary ip-PPP with fertilization was not statistically significant (*p* of $\text{interaction} = 0.53$).

There was a significant positive association between urinary BDCIPP and the number of total oocytes (18% increase, $p - \text{trend} = 0.04$) and a nonsignificant increase in the number of mature oocytes (15% increase, $p - \text{trend} = 0.10$) retrieved in an IVF cycle. For endometrial lining thickness, we observed a nonsignificant decline in adjusted means from the highest to lowest quartile of urinary DPHP (4% decrease, $p - \text{trend} = 0.15$). Similar trends with oocyte count were not observed for DPHP, ip-PPP, or $\Sigma\text{PFR}$ (*p*-trends $> 0.3$). No other associations were observed between urinary metabolites and the other early developmental outcomes, and unadjusted results were similar (Table S3).

Discussion {#s4}
==========

As far as we are aware, this is the first study to explore associations in an epidemiologic study on the effects of PFRs on female reproduction. We used the model of IVF to investigate human reproduction and early pregnancy outcomes, ranging chronologically from oocyte retrieval, oocyte fertilization, embryo quality, and implantation to clinical pregnancy and live birth. The sum of the urinary PFR metabolites was associated with reduced probability of successful fertilization, implantation, clinical pregnancy, and live birth. These findings are clinically relevant, as the adjusted proportion of live births in the highest quartile of $\Sigma\text{PFR}$ was 0.30 as compared to 0.48 in the lowest quartile (adjusted difference in $\text{proportions} = 0.18$). GM concentrations of the PFR metabolites in our study population were similar to or lower than other adult populations in the United States, Norway, and Australia; thus, these exposure levels are not abnormal or high ([@c4]; [@c6]; [@c7]; [@c10]; [@c12]; [@c18]; [@c22]; [@c30]) (Table S4).

Animal studies indicate that PFRs may adversely affect female reproduction through disruption of regulatory pathways mediated by the hypothalamus--pituitary--gonadal axis. For example, studies in zebrafish have observed decreased fecundity (hatching and survival) with independent exposures to TDCIPP and TPHP ([@c20]; [@c33]). Evidence of hormone disruption in zebrafish includes increased plasma E~2~, testosterone, and vitellogenin as well as increased triiodothyronine ($T_{3}$) and decreased thyroxine ($T_{4}$) ([@c20]; [@c33], [@c34]). Studies of chicken embryos have observed delayed hatching as well as declines in plasma thyroxine and cholesterol ([@c13], [@c14]). Human studies have also observed an association between low pregnancy levels of estradiol and fetal loss ([@c26]), and it is well known that subclinical hypothyroidism can adversely affect fertility ([@c1]; [@c3]; [@c27]; [@c32]).

Strengths of our study include the prospective study design, preconception measurement of exposure using repeated urine samples (which is necessary for short-lived biomarkers like the PFR metabolites), state-of-the-art measurement of PFR exposure biomarkers, assessment of early developmental outcomes (i.e., fertilization, implantation) that are not observable in non-IVF populations, clinical outcome data obtained from electronic medical records, and control for potential confounders. One limitation of this analysis is that we did not consider the male partner\'s exposure, which may be correlated with his female partner and could contribute to the observed association. Our findings are generalizable to the infertility clinic population, which is sizable ([@c29]), and may be more broadly generalizable, assuming that women undergoing IVF have similar biological responses to PFR exposure as women not undergoing IVF. Our findings may also be more relevant and generalizable to older women, as the mean age of women in our study population was 35 y. As each outcome is dependent on the previous, a larger sample would be required to differentiate between independent effects on implantation, clinical pregnancy, and live birth.

In conclusion, using IVF as a model to investigate human reproduction and pregnancy outcomes, we found that concentrations of some urinary PFR metabolites were inversely associated with proportions of successful fertilization, implantation, clinical pregnancy, and live birth. These results highlight the potential reproductive effects of low-level exposure (i.e., background exposure levels of the general population) to PFRs and adverse IVF outcomes. Future research should focus on potential interactions between PFRs and other chemicals (i.e., mixtures analysis) that adversely affect reproductive health and also explore the potential effect of PFRs on male reproductive health.

Supplemental Material
=====================

###### 

Click here for additional data file.
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